Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2021

View Archived Issues

Recombinant HA stably presented on immunogenic liposomes improves immunogenicity in animal models

Discovery of a novel calcitonin gene-related peptide receptor antagonist azepinone series

Targeting hypoxia-induced metastatic genes shows therapeutic potential in uveal melanoma

FDA clears IND for phase I study of Protollin as treatment of AD

New glucocorticoid receptor modulators identified at Medshine Discovery

DNA-dependent protein kinase inhibitors discovered at Chengdu Baiyu Pharmaceutical

Enyo reports promising phase II data for vonafexor in patients with chronic hepatitis B

Beijing Kang Dini Pharmaceutical presents new IL-8 expression inhibitors

Jiangsu Simcere Pharmaceutical R&D discovers MAT2A inhibitors

Deuterated GC-376 variants show efficacy in model of SARS-CoV-2 infection

Addition of GEN-1 to standard NAC shows safety and efficacy in phase I ovarian cancer study

Changes in SavaDx and plasma P-tau181 confirm treatment effect of simufilam in AD

RemeGen receives Australian ethics approval for phase I trial of ADC RC-118

Topline phase II data with Sarconeos in sarcopenia

Evolutionary modeling warns of COVID-19 vaccine resistance

Trk-A inhibitor E-2511 restores cholinergic neurons in transgenic models of Alzheimer's disease

Lundbeck studies Lu-AG-06466 in phase I for fibromyalgia

Lundbeck opens phase I study of Lu-AG-09222 in headache model

China NMPA accepts IND for phase I study of CAN-103 for Gaucher's disease

U.K. MHRA clears initiation of first-in-human study of HMBD-001 in advanced cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...